241 related articles for article (PubMed ID: 29543897)
1. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Elbasha E; Greaves W; Roth D; Nwankwo C
J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
[TBL] [Abstract][Full Text] [Related]
3. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
Elbasha EH; Robertson MN; Nwankwo C
Aliment Pharmacol Ther; 2017 Feb; 45(3):455-467. PubMed ID: 27910116
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Choi DT; Puenpatom A; Yu X; Erickson KF; Kanwal F; El-Serag HB; Kramer JR
Antiviral Res; 2020 Feb; 174():104698. PubMed ID: 31862503
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China.
Chen P; Ma A; Liu Q
Clin Drug Investig; 2018 Nov; 38(11):1031-1039. PubMed ID: 30194584
[TBL] [Abstract][Full Text] [Related]
8. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
10. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
Kumada H; Suzuki Y; Karino Y; Chayama K; Kawada N; Okanoue T; Itoh Y; Mochida S; Toyoda H; Yoshiji H; Takaki S; Yatsuzuka N; Yodoya E; Iwasa T; Fujimoto G; Robertson MN; Black S; Caro L; Wahl J
J Gastroenterol; 2017 Apr; 52(4):520-533. PubMed ID: 27873094
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Caro L; Wenning L; Feng HP; Guo Z; Du L; Bhagunde P; Fandozzi C; Panebianco D; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
Eur J Clin Pharmacol; 2019 May; 75(5):665-675. PubMed ID: 30680407
[TBL] [Abstract][Full Text] [Related]
13. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H; Martin P; Pol S; Londoño MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W
Lancet; 2015 Oct; 386(10003):1537-45. PubMed ID: 26456905
[TBL] [Abstract][Full Text] [Related]
14. Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam.
Nwankwo C; Corman SL; Elbasha EH
J Infect Public Health; 2019; 12(4):502-508. PubMed ID: 30711348
[TBL] [Abstract][Full Text] [Related]
15. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
Bruchfeld A; Roth D; Martin P; Nelson DR; Pol S; Londoño MC; Monsour H; Silva M; Hwang P; Arduino JM; Robertson M; Nguyen BY; Wahl J; Barr E; Greaves W
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):585-594. PubMed ID: 28576451
[TBL] [Abstract][Full Text] [Related]
16. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
Jacobson IM; Poordad F; Firpi-Morell R; Everson GT; Verna EC; Bhanja S; Hwang P; Caro L; Robertson M; Charles ED; Platt H
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00007. PubMed ID: 30939489
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
Suenaga R; Suka M; Hirao T; Hidaka I; Sakaida I; Ishida H
PLoS One; 2021; 16(4):e0248748. PubMed ID: 33793594
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Liu J; Guo M; Ke L; You R
Front Public Health; 2022; 10():836986. PubMed ID: 35646774
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Brown A; Hézode C; Zuckerman E; Foster GR; Zekry A; Roberts SK; Lahser F; Durkan C; Badshah C; Zhang B; Robertson M; Wahl J; Barr E; Haber B;
J Viral Hepat; 2018 May; 25(5):457-464. PubMed ID: 29152828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]